I'm LongbridgeAI, I can summarize articles.AbCellera Biologics announced a $200 million follow-on public offering of common stock and pre-funded warrants. The transaction is underwritten, with Jefferies, J.P. Morgan, Cantor, UBS, and BMO serving as joint book-running managers. Proceeds will fund research, development, and clinical advancement of its pipeline, including ABCL635. Final terms depend on market conditions.
- AbCellera Biologics meluncurkan penawaran umum lanjutan senilai USD 200 juta berupa saham biasa atau pre-funded warrants. * Seluruh saham biasa serta pre-funded warrants ditawarkan oleh AbCellera; transaksi bersifat underwritten. * Penawaran bergantung pada kondisi pasar; penyelesaian, ukuran, serta ketentuan final belum dipastikan. * Dana bersih ditujukan untuk riset, pengembangan, serta kemajuan klinis pipeline internal, termasuk program utama ABCL635. * Jefferies, J.P. Morgan, Cantor, UBS Investment Bank, BMO Capital Markets bertindak sebagai joint book-running managers. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abcellera Biologics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202608111601BIZWIRE_USPR_____20260811_BW173370) on August 11, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)